4441-57-0

Basic information

• Product Name: 4-CYCLOHEXYL-1-BUTANOL
• Synonyms: 4-CYCLOHEXYL-1-BUTANOL;4-CYCLOHEXYLBUTAN-1-OL;CYCLOHEXANEBUTANOL;cyclohexylbutan-1-ol;Cyclohexane-1-butanol;4-Cyclohexyl-1-butanol,99%;4-Cyclohexyl-1-butanol 99%;4-Cyclohexyl-1-butanol >=95%
• CAS NO: 4441-57-0
• Molecular Formula: C₁₀H₂₀O
• Molecular Weight: 156.27
• EINECS: 224-664-8
• Mol File: 4441-57-0.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 103-104 °C4 mm Hg(lit.)
• Flash Point: 228 °F
• Appearance: /
• Density: 0.902 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.0103mmHg at 25°C
• Refractive Index: n20/D 1.466(lit.)
• CAS DataBase Reference: 4-CYCLOHEXYL-1-BUTANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CYCLOHEXYL-1-BUTANOL(4441-57-0)
• EPA Substance Registry System: 4-CYCLOHEXYL-1-BUTANOL(4441-57-0)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 4441-57-0(Hazardous Substances Data)

Usage

General Description

4-CYCLOHEXYL-1-BUTANOL is a chemical compound with the molecular formula C10H20O. It is a colorless, viscous liquid with a mild, sweet odor. This chemical is commonly used as a solvent and a fragrance ingredient. It is also utilized in the production of various other chemicals and pharmaceuticals. Additionally, 4-CYCLOHEXYL-1-BUTANOL is known for its potential as a neuroprotective agent and has been studied for its potential use in treating neurodegenerative diseases. However, it is important to handle this chemical with caution as it can be harmful if ingested or inhaled and may cause skin and eye irritation upon contact.

InChI:InChI=1/C10H20O/c11-9-5-4-8-10-6-2-1-3-7-10/h10-11H,1-9H2

Upstream product

• 1821-12-1 4-Phenylbutyric acid 
• 201230-82-2 carbon monoxide 
• 2114-42-3 allylcyclohexane 
• 1439367-44-8 4-cyclohexylbutyl 2-oxopyridine-1(2H)-carboxylate 
• 62018-57-9 (E)-but-2-en-1-ylcyclohexane 
• 128584-32-7 ethyl N-[7-chloro-3-[2,3-O-(1-methylethylidene)-5-O-(2H-tetrahydropyran-2-yl)-β-D-ribofuranosyl]-3H-imidazo[4,5-b]pyridin-5-yl]-carbamate 
• 4441-63-8 4-cyclohexylbutanoic acid 
• 51953-07-2 4-cyclohexylbutyl 4-methylbenzenesulfonate 
• 4442-79-9 cyclohexylethan-1-ol 
• 75-21-8 oxirane 
• 1647-26-3 1-bromo-2-cyclohexylethane 
• 64-17-5 ethanol 

Downstream Products

• 1860-41-9 4-cyclohexylbutyraldehyde 
• 809273-84-5 cyclohexylbutyl acetoacetate 
• 196707-77-4 bis[(4-cyclohexyl)butyl] 1,4-dihydro-2,6-dimethyl-4-(1-methyl-5-nitroimidazol-2-yl)-3,5-pyridinedicarboxylate 
• 1034706-02-9 2-[2-(4-cyclohexylbutoxy)-2-oxoethyl]benzoic acid 
• 906100-43-4 2-(4-cyclohexylbutyl)isoindoline-1,3-dione 
• 787581-11-7 (4-isocyanatobutyl)cyclohexane 
• 454646-68-5 3-(1H-imidazol-4-yl)propyl 4-cyclohexylbutylcarbamate hydrogen maleate 

Relevant articles and documents

GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE

The present invention discloses a glycoside compound represented by Formula III, and a preparation method, a composition, use and an intermediate thereof. The glycoside compound provided in the present invention has simple preparation method, can significantly increase the expression of VEGF-A mRNA, and is effective in promoting the angiogenesis. This provides a reliable guarantee for the development of drugs with pro-angiogenic activity for treating cerebral infarction cerebral stroke, myocardial infarction, and ischemic microcirculatory disturbance of lower limbs.

CYCLOALKYL-CONTAINING CARBOXYLIC ACIDS AND USES THEREOF

The present application discloses a compound of formula (I) or a salt thereof: (I) and compositions comprising such compound or salt thereof. The use of such compound, salt thereof or composition comprising same for treating anemia or leukopenia, fibrosis, cancer, hypertension and/or a metabolic condition in a subject is also disclosed.

CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS

Described herein are compounds and pharmaceutical compositions which inhibit N-acylethanolamine acid amidase (NAAA). Described herein are methods for synthesizing the compounds set forth herein and methods for formulating these compounds as pharmaceutical compositions which include these compounds. Also described herein are methods of inhibiting NAAA in order to sustain the levels of palmitoylethanolamide (PEA) and other N-acylethanolamines (NAE) that are substrates for NAAA, in conditions characterized by reduced concentrations of NAE. Also, described here are methods of treating and ameliorating pain, inflammation, inflammatory diseases, and other disorders in which modulation of fatty acid ethanolamides is clinically or therapeutically relevant or in which decreased levels of NAE are associated with the disorder.